Hypercholesterolemia Clinical Trial
— CEPHEUSOfficial title:
Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
| Verified date | December 2010 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Philippines: Bureau of Food and Drugs |
| Study type | Observational |
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
| Status | Completed |
| Enrollment | 8000 |
| Est. completion date | December 2008 |
| Est. primary completion date | December 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - 2 or more risk factors (according to NCEP ATP III guideline) - Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks. Exclusion Criteria: - Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site). - Previous enrolment or randomisation of treatment in the present study. - Participation in a clinical study during the last 90 days. |
Observational Model: Case-Only, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| China | Research Site | Hong Kong | Hong Kong |
| Indonesia | Research Site | Bandung | West Java |
| Indonesia | Research Site | Jakarta | DKI Jakarta |
| Indonesia | Research Site | Medan | North Sumatra |
| Indonesia | Research Site | Semarang | Central Java |
| Indonesia | Research Site | Sidoarjo | East Java |
| Indonesia | Research Site | Surabaya | East Java |
| Korea, Republic of | Research Site | Bu-cheon | Gyeong-gi |
| Korea, Republic of | Research Site | Bu-san | |
| Korea, Republic of | Research Site | Bundang | Gyeong-gi |
| Korea, Republic of | Research Site | Cheon-an | Chung-Cheong-nam-do |
| Korea, Republic of | Research Site | Dae-gu | |
| Korea, Republic of | Research Site | Dae-jeon | |
| Korea, Republic of | Research Site | Gu-ri | Gyeong-gi |
| Korea, Republic of | Research Site | Gwangju | |
| Korea, Republic of | Research Site | Il-san | Gyeong-gi |
| Korea, Republic of | Research Site | In-cheon | |
| Korea, Republic of | Research Site | Je-ju | |
| Korea, Republic of | Research Site | Ma-san | Gyung-sang-nam-do |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Su-won | Gyeong-gi |
| Korea, Republic of | Research Site | Ul-san | |
| Malaysia | Research Site | Ampang | Selangor |
| Malaysia | Research Site | Bandar Sunway | Selangor |
| Malaysia | Research Site | Bangsar | Kuala Lumpur |
| Malaysia | Research Site | Batu Caves | Selangor |
| Malaysia | Research Site | Hulu Selangor | Selangor |
| Malaysia | Research Site | Kepong | Kuala Lumpur |
| Malaysia | Research Site | Klang | Selangor |
| Malaysia | Research Site | Kuala Lumpur | |
| Malaysia | Research Site | Petaling Jaya | Selangor |
| Malaysia | Research Site | Port Klang | Selangor |
| Malaysia | Research Site | Puchong | Kuala Lumpur |
| Malaysia | Research Site | Sekinchan | Selangor |
| Malaysia | Research Site | Selangor | |
| Malaysia | Research Site | Seri Kembangan | Selangor |
| Malaysia | Research Site | Setapak | Kuala Lumpur |
| Malaysia | Research Site | Shah Alam | Selangor |
| Malaysia | Research Site | Subang | Selangor |
| Malaysia | Research Site | Subang Jaya | Selangor |
| Malaysia | Research Site | Sungai Buloh | Selangor |
| Philippines | Research Site | Baguio | Benguet |
| Philippines | Research Site | Davao | |
| Philippines | Research Site | Iloilo | |
| Philippines | Research Site | Lipa | Batangas |
| Philippines | Research Site | Manila | |
| Taiwan | Research Site | Kaohsiung | |
| Taiwan | Research Site | Taichung | |
| Taiwan | Research Site | Tainan | |
| Taiwan | Research Site | Taipei | |
| Taiwan | Research Site | Taoyuan | |
| Thailand | Research Site | Bangkoknoi | Bangkok |
| Thailand | Research Site | Dusit | Bangkok |
| Thailand | Research Site | Klongluang | Pathumthani |
| Thailand | Research Site | Muang | ChiangMai |
| Thailand | Research Site | Pathumwan | Bangkok |
| Thailand | Research Site | Ratchathewi | Bangkok |
| Vietnam | Research Site | Hanoi | |
| Vietnam | Research Site | Hcmc |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
China, Indonesia, Korea, Republic of, Malaysia, Philippines, Taiwan, Thailand, Vietnam,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP ? guidelines(overall and by country) | After collecting all Patient Record Form. | No | |
| Secondary | The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP ? guidelines for several subject subsets. | After collecting all Patient Record Form. | No | |
| Secondary | The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATP? guidelines and patient and physician variables. | After collecting all Patient Record Form. | No | |
| Secondary | The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. | After collecting all Patient Record Form. | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
| Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
| Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
| Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
| Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
| Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
| Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
| Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
| Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
| Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
| Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
| Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
| Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
| Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
| Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
| Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
| Completed |
NCT01478789 -
Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans
|
N/A | |
| Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A |